Jennifer Michelle Pearson

US Patent:

20220387358, Dec 8, 2022

Filed:

Nov 9, 2020

Appl. No.:

17/775213

Inventors:

- Charlottesville VA, US
David J. Feith - Palmyra VA, US
Jennifer M. Pearson - Charlotte NC, US
Mark Kester - Afton VA, US
Tye Deering - Charlottesville VA, US
Todd Fox - Charlottesville VA, US
Helena Woodvine Snyder - Crozet VA, US
Anuradha Illendula - Crozet VA, US

International Classification:

A61K 31/164
A61K 31/635
A61K 31/706
A61K 9/127
A61K 9/00
A61P 35/02

Abstract:

Provided are methods for treating a disease, disorder, or condition associated with an acid ceramidase (AC) biological activity. The methods include administering to a subject in need thereof a composition including an AC inhibitor and at least one additional active agent, such as a C6-ceramide nanoliposome (CNL); an inhibitor of a Bcl-2 family protein; a hypomethylating agent; an intensive chemotherapeutic agent such as cytarabine (AraC) and/or daunorubicin; a Hedgehog pathway inhibitor; a targeted agent, such as a FLT2 inhibitor or a EDH1/2 inhibitor; and/or an antibody drug conjugate that targets, for example, CD-33. The composition can include N-[(2S,3R)-1,3-dihydroxyoctadecan-2-yl]2-chloroacetamide (SACLAC) or a pharmaceutically acceptable salt thereof and at least one additional active agent. The disease, disorder, or condition associated with the AC biological activity can be a cancer, such as acute myeloid leukemia (AML).

US Patent:

20200276138, Sep 3, 2020

Filed:

Apr 27, 2018

Appl. No.:

16/609124

Inventors:

- Charlottesville VA, US
- Barcelona, ES
- Madrid, ES
Josefina Casas - Barcelona, ES
David J. Feith - Palmyra VA, US
Jennifer M. Pearson - Charlottesville VA, US
Antonio Delgado Cirilo - Barcelona, ES

International Classification:

A61K 31/164
A61P 35/02

Abstract:

The present application provides novel compositions and methods for treating acute myeloid leukemia (AML). Compounds of the invention are acid ceramidase inhibitors, reduce AML cell viability, inhibit AML cell proliferation, increase cell death of AML cells, and induce apoptosis in AML cells. A primary compound of the invention is SACLAC: 2-chloro-N-((2S,3R)-1,3-dihydroxyoctadecan-2-yl)acetamide. The bromine analog of SACLAC (SABRAC: 2-bromo-N-((2S,3R)-1,3-dihydroxyoctadecan-2-yl)acetamide) is also useful for treating AML. SACLAC has much better activity than other know drugs used to treat AML.